News
VKTX
68.86
+5.82%
3.79
BUZZ-U.S. STOCKS ON THE MOVE-Loar, Regeneron, Intel
U.S. Stocks slumped on Thursday. Dow Jones Industrial Average was down 1.15% and the S&P 500 was down 0.76%. Most megacaps fell after Meta Platforms' quarterly results. Newmont Corp. Was the top percentage gainer on the NYSE and the Nasdaq.
Reuters · 6h ago
BUZZ-U.S. STOCKS ON THE MOVE-Viking, Alphabet, Dover
U.S. Stocks were sharply lower on Thursday. The Dow Jones Industrial Average was down 1.58% and the S&P 500 and Nasdaq Composite were also down. Meta Platforms dropped 12.7% after dour quarterly results. Newmont Corp was the top percentage gainer on the S.P. 500 and the Nasdaq.
Reuters · 7h ago
BUZZ-Viking climbs on smaller-than-expected quarterly loss
Shares of drug developer Viking Therapeutics rise 2.5% to $66.68. Co reports smaller-than-expected quarterly loss of 26 cents/shr. Company's experimental tablet reduced weight by as much as 3.3% in a small early-stage trial.
Reuters · 9h ago
VIKING THERAPEUTICS SHARES DOWN 1.3% AFTER Q1 RESULTS
Reuters · 10h ago
Analysts Offer Insights on Healthcare Companies: CalciMedica (CALC), Acrivon Therapeutics, Inc. (ACRV) and Viking Therapeutics (VKTX)
TipRanks · 11h ago
Viking Therapeutics, Inc. Form 10-Q for the Quarter Ended March 31, 2024
Press release · 11h ago
Viking Therapeutics Price Target Maintained With a $90.00/Share by HC Wainwright & Co.
Dow Jones · 12h ago
HC Wainwright & Co. Reiterates Buy on Viking Therapeutics, Maintains $90 Price Target
Benzinga · 12h ago
Analysts Offer Insights on Healthcare Companies: Encompass Health (EHC), Universal Health (UHS) and Viking Therapeutics (VKTX)
TipRanks · 12h ago
Analysts Offer Insights on Healthcare Companies: Viking Therapeutics (VKTX), Acrivon Therapeutics, Inc. (ACRV) and Gain Therapeutics (GANX)
TipRanks · 13h ago
VKTX Stock Earnings: Viking Therapeutics Beats EPS for Q1 2024
Viking Therapeutics reported earnings per share of -26 cents for the first quarter of 2024. The company did not report any revenue for the quarter. This was above the analyst estimate of -28 cents. Viking Therapeutic is a biopharmaceutical company.
Investorplace · 22h ago
Viking Therapeutics down 4% despite quarterly bottom line beat
Shares of Viking Therapeutics down 4% despite quarterly bottom line beat. The company's Q1 2024 financial results beat on the bottom line, but did not report any revenue. Viking's net loss in the quarter widened to $27.4M from $19.5M in Q1 2023.
Seeking Alpha · 1d ago
Viking Therapeutics Reports Q1 Results: 'An Exceptional Period' Says CEO
Viking Therapeutics reported its first-quarter financial results after the bell Wednesday. The company reported quarterly losses of 26 cents per share. Viking ended the first quarter with cash, cash equivalents and short-term investments of $963 million. Viking beat the analyst consensus estimate of losses of 28 cents by 7.14%.
Benzinga · 1d ago
Viking Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Viking Therapeutics Inc reports results for the quarter ended in March. The company reported a quarterly adjusted loss of 26 cents per share. The mean expectation of ten analysts was for a loss of 28 cents. Reported revenue was zero; analysts expected zero. Shares had fallen by 20.8% this quarter and gained 248.9% this year.
Reuters · 1d ago
Viking Therapeutics GAAP EPS of -$0.26 beats by $0.02
Viking Therapeutics GAAP EPS of -$0.26 beats by $0.02. As of the end of the first quarter, the company held approximately $963 million in cash, cash equivalents, and marketable securities. The company's Q1 GAAP revenue of $1.2 million was higher than expected.
Seeking Alpha · 1d ago
*Viking Therapeutics 1Q Rev $0.00 >VKTX
Dow Jones · 1d ago
Viking Therapeutics Q1 EPS $(0.26) Beats $(0.28) Estimate
Benzinga · 1d ago
VIKING THERAPEUTICS- RESULTS FROM PHASE 2 VENTURE TRIAL OF GLP-1/GIP AGONIST VK2735 IN OBESITY SHOWED UP TO 13.1% PLACEBO-ADJ WEIGHT LOSS AT 13 WEEKS
Reuters · 1d ago
VIKING THERAPEUTICS REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
Reuters · 1d ago
VIKING THERAPEUTICS Q1 INCOME FROM OPERATIONS USD -34.073 MILLION VS. IBES ESTIMATE USD -30.7 MILLION
Reuters · 1d ago
More
Webull provides a variety of real-time VKTX stock news. You can receive the latest news about Viking Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About VKTX
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for treatment of metabolic and endocrine disorders. The Company's clinical programs include VK2809, an orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders, which is being evaluated in a Phase II b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. The Company is developing VK0214, which is also an orally available, tissue and receptor-subtype selective agonist of TRb for X-linked adrenoleukodystrophy (X-ALD), a rare X-linked, inherited neurological disorder characterized by a breakdown in the protective barriers surrounding brain and nerve cells. It is also developing VK2735, a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the treatment of various metabolic disorders.